Core Insights - Nexalin Technology, Inc. is hosting a webinar on June 3, 2025, to discuss its innovative approach to mental healthcare using its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology [1][2] - The company is positioned in a $537 billion mental health market, with international regulatory approvals and U.S. expansion plans underway [2] - Nexalin's technology includes real-time AI-driven patient monitoring and aims to provide scalable, at-home treatment options [2] Company Overview - Nexalin designs and develops non-invasive neurostimulation products aimed at addressing the global mental health epidemic [4] - The company's devices are believed to penetrate deep brain structures associated with mental health disorders, enhancing patient response without adverse side effects [4] - The Nexalin Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, and Oman [4]

HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has successfully enrolled the first patients in its clinical trial at the University of California, San Diego (UCSD), in collaboration with the VA San Diego Healthcare System (San Diego VA). The company began treatment of the first patients this week with the Nexalin HALO™. This significa ...

Company Overview - Nexalin Technology, Inc. is focused on developing innovative neurostimulation products aimed at addressing the global mental health epidemic, utilizing non-invasive bioelectronic medical technology [4] - The company's neurostimulation devices are designed to penetrate deep brain structures associated with mental health disorders, potentially enhancing patient response without adverse side effects [4] Upcoming Event - Nexalin will host a webinar on April 3, 2025, at 4:15 p.m. ET, featuring CEO Mark White, who will discuss the company's clinical data and advancements in its Gen-3 HALO™ Clarity & Virtual Clinic model [2][3] - The webinar will include a live Q&A session, allowing investors to engage directly with the CEO [2] Market Potential - Nexalin's solutions have demonstrated clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries, which affect millions and have limited effective treatments [2] - The mental health market is projected to reach $537 billion by 2030, indicating substantial growth potential for Nexalin's products [2]